ArticleRadiology case reports2025
A case report from osteosarcoma to SEF: A diagnostic pitfall with a rare metastatic pattern.
Article in Radiology case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sclerosing epithelioid fibrosarcoma (SEF) is a rare and aggressive variant of fibrosarcoma with a deceptively bland histologic appearance but high metastatic potential, often leading to misdiagnosis and delayed treatment. We present a case of a 21-year-old male initially diagnosed with osteosarcoma due to progressive right proximal thigh pain and swelling. He was treated with perioperative chemotherapy (cisplatin and doxorubicin) and underwent limb-salvage surgery, but postoperative molecular testing revealed an Ewing Sarcoma Receptor 1 (EWSR1) gene rearrangement, confirming SEF. Despite surgery and systemic chemotherapy, the patient developed metastatic disease involving the lungs, adrenal glands, and spine. Aggressive treatments including multiple surgeries, radiotherapy, and chemotherapy (gemcitabine-docetaxel, ifosfamide) failed to halt disease progression. The patient transitioned to palliative care and eventually passed away. SEF is known for its slow progression, high metastatic potential, and resistance to conventional therapies. This case highlights the diagnostic challenges of SEF, the importance of molecular testing for accurate diagnosis, and the need for novel treatment strategies, as SEF remains highly resistant to current therapeutic options.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.